Accessibility links Skip to main content

Reviewing a PQR (Product Quality Review) as a QP

One of the important aspects of an effective Pharmaceutical Quality System is the Annual Product Review (APR) or Product Quality Review (PQR). As documented in Volume IV, Chapter 1 of the EU GMP Guide, these reviews are required for all authorised medicinal products, including export only products and they should be conducted with the objective of ‘verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product, to highlight any trends and to identify product and process improvements.’

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading

Why are they done?

There are several reasons for preparing PQRs.

Apart from being a legal requirement to perform these reviews, they allow pharmaceutical companies to gain an in-depth understanding of the product, manufacturing processes, trends and risks.

They are useful to review whether re-validation is required for any systems and if new Corrective and Preventative Actions (CAPAs) need to be set up.

The benefits also include a basis for the adjustment of process, raw material and excipient specifications where necessary, better process controls and a reduction in Quality Defects.

PQRs result in enhanced product and process knowledge and they provide a more structured system for proactive improvement.

How are they done?

Responsibilities should be clearly defined for the preparation of PQRs. Typically, information is collected and analysed by each department/ Subject Matter Expert within the responsible company and this information is then compiled into a report. The reports are then reviewed and approved by the Quality Department. Where the product manufacture involves a complex supply chain with Contract Manufacturing Organisations (CMOs) and Contract Laboratory Organisations (CLOs), input from the various parties is needed. Once fully reviewed, recommendations and actions are identified for improvements or where risks are highlighted. Qualified Persons who are responsible for disposition of the product reviewed should be involved in the review of the PQR.

When are they done?

PQRs are usually prepared annually covering the retrospective review of a calendar year and ideally, they should be available no later than 3 months after the review period.

What topics should they cover?

The PQR should include a review of the following topics for the duration of the review period along with statistical analysis where applicable:

  • The batches manufactured including any major issues identified
  • Active Product Ingredients, raw materials and packaging materials, especially those from new sources and in particular the review of supply chain traceability of active substances.
  • Manufacturing & Packaging processes
  • In Process Controls (IPCs) and Critical Process Parameters (CPPs)
  • Finished product results
  • Out of Specification (OOS) and Out of Trend (OOT) results
  • Rejected materials/ batches
  • Deviations/ Non-conformances, their related investigations and the effectiveness of resultant corrective and preventive actions (CAPAs) taken
  • Change controls
  • Product returns, recalls and customer complaints and the investigations performed
  • Regulatory actions including Marketing Authorisation variations submitted, granted or refused and any post marketing commitments
  • Validation studies completed/ required and a review of Continuous Process Verification (CPV)
  • Results of the stability monitoring programme and any adverse trends.
  • Supplier qualification status (audits and Quality Technical Agreements)
  • Risk evaluation
  • For products that require importation testing from a third country, comparison of results obtained from importation testing and the third country laboratory in addition to the effectiveness of the sampling procedure

What challenges do they present?

One of the challenges associated with producing PQRs is keeping on top of the batch data. It is important to have clear roles defined within a written procedure to avoid any confusion and to monitor progress at regular intervals. This will make sure it isn’t a last minute effort and consistent data collection and review takes place. It can also be challenging to co-ordinate the input from several companies when the Supply Chain is more complicated but once there is proper communication and planning, any issues or delays should be avoidable.

Conclusion

In the Pharma world, data review, knowledge management and continuous improvement are key aspects of product Quality Assurance and patient safety. A detailed and thorough PQR facilitates process monitoring and can help to identify potential problems or process drift before they before they become an issue.

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

20 Feb 2026

Quality & Regulatory Implications from EU Critical Medicines Act

The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.

28 Jan 2026

Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?

As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.